An improved and scalable process for the production of rivastigmine tartrate is reported. The improved process provides rivastigmine tartrate at considerably lower cost and allows the omission of hazardous chemicals. The overall yield is increased from 4.66% (reported process) to 17% with the improved process.
Keywords: Rivastigmine tartrate, a cholinesterase inhibitor, alzheimer's disease, improved process, impurities